If TIGIT and PD-1 are prominent players in oesophageal tissue for controlling immune activation, then targeting both TIGIT and PD-1 in tandem to remove the brakes on anti-cancer immunity may be an effective combination to test in OAC. This evidence concerns the gene TIGIT and cancer.